Actinium Pharmaceuticals, Inc. News | Stock Guides Healthcare | Biotechnology | USA Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Actinium is a micro-cap company, with a market capitalization below $100 million. The company's drug candidates are significantly differentiated, and not much competition exists in this otherwise crowded biotech space. Lomab-B enrollment is picking up steam, and the drug is likely to be approved, due to lack of viable alternatives.
